ImmunityBio, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 26CA.F | BNTX | 4564.T | CGON | IOVA | 6YG.MU | |
|---|---|---|---|---|---|---|
| Market cap | 7.58B | 21.43B | 6.94B | 5.76B | 3.50B | 1.31B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -8.1 | -15.8 | -0.8 | -21.5 | -39.5 | — |
| Price/book | -8.1 | 1.1 | 3.0 | 5.6 | 4.8 | 3.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +328.22% | −12.24% | −26.09% | +70.60% | +276.62% | −6.85% |
| Today | −9.03% | −4.71% | 0.00% | −4.03% | −11.09% | −2.99% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All 26CA.F news ›ImmunityBio Treats First Patients In Europe With Anktiva Plus BCG – Retail Calls It A ‘Great Opening Act’ For Q3 Earnings
ImmunityBio (IBRX) clocked a major milestone in its European expansion on Wednesday, after the biotech firm said the first patients in Europe received its bladder cancer treatment, Anktiva, in combination with Bacillus Calmette-Guérin…
ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
The treatment milestone follows the European Commission’s conditional marketing authorization of ANKTIVA in February 2026 for the treatment of adult patients with BCG-unresponsive NMIBC with carcinoma in situ (CIS), with or without…
Anktiva Vs Keytruda: ImmunityBio Exec Chair Slams FDA For Double Standards In Approvals
ImmunityBio’s executive chairman, Patrick Soon-Shiong, took direct aim at the FDA this weekend, accusing regulators of fast-tracking Merck’s blockbuster cancer drug Keytruda while keeping Anktiva boxed into a single bladder cancer…
Financial Review: MDxHealth (NASDAQ:MDXH) and ImmunityBio (NASDAQ:IBRX)
Posted by Michael Walen on Nov 2nd, 2026 ImmunityBio (NASDAQ:IBRX – Get Free Report) and MDxHealth (NASDAQ:MDXH – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on…
Expanded Use for ImmunityBio Drug
Anktiva can now treat a more common form of bladder cancer. Culver City-based immunotherapy company ImmunityBio Inc. has gained U.S. Food and Drug Administration approval for expanded use of its primary drug Anktiva to treat a more common…
ImmunityBio (IBRX) Expected to Announce Earnings on Tuesday
Posted by Mitch Edgeman on Oct 27th, 2026 IBRX opened at $7.81 on Tuesday. The company has a market cap of $8.28 billion, a P/E ratio of -8.05 and a beta of 0.02. The business’s 50-day moving average price is $8.65 and its 200-day moving…
ImmunityBio (IBRX): November ANKTIVA Trial Results Could Support Expanded FDA Filing?
ImmunityBio (IBRX) completed database lock for its 366-patient QUILT-2.005 trial evaluating ANKTIVA plus BCG in BCG-naïve bladder cancer. Topline results are expected in November 2026, with an FDA supplemental application planned for Q4…
ImmunityBio Locks Anktiva Trial Database, Eyes November Results As FDA Filing Nears
ImmunityBio (IBRX) shares were in focus on Wednesday after the immunotherapy company said it had completed the database lock for a 366-patient trial testing ANKTIVA plus BCG in patients with BCG-naïve non-muscle invasive bladder cancer…
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
The database lock follows the completion of the data review, verification, and reconciliation of all 366 randomized patients, allowing the final efficacy analysis to proceed. The trial is designed to determine whether adding ANKTIVA to…
ImmunityBio: FDA expands ANKTIVA bladder cancer use
VivoPower Signs Definitive Heads of Agreement with Open Innovation AI to Develop Secure Sovereign AI Data Centers Across the Nordics, Mainland Europe, the GCC and selective countries in Asia BioCryst Announces U.S. FDA Approval of…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- defenseworld.net3
- stocktitan.net3
- stocktwits.com3
- themarketsdaily.com3
- tradingview.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 21 articles, not a forecast.